Reaction

Nephritis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,266 reports · 82 co-occurring drugs

As of the last recalculation, Nephritis appears in 3,266 FAERS reports alongside 82 co-occurring drug terms. The strongest observed disproportionality signal is ATEZOLIZUMAB (PRR 34.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Atezolizumab	196	34.2	34.3
Pembrolizumab	448	31.3	31.4
Pemetrexed	97	29.7	29.8
Pemetrexed Disodium	140	24.4	24.5
Ipilimumab	151	23.3	23.4
Durvalumab	67	21.4	21.5
Nivolumab	263	18.8	18.8
Carboplatin	209	11.1	11.2
Axitinib	32	10.6	10.6
Anti-Thymocyte Globulin (Rabbit)	13	10.3	10.3
Belimumab	47	9.6	9.6
Piperacillin And Tazobactam	19	9.5	9.5
Amphotericin B	18	9.2	9.2
Piperacillin Sodium And Tazobactam Sodium	24	7.8	7.9
Cefuroxime	14	7.8	7.8
Ampicillin	10	7.7	7.7
Ampicillin Sodium	10	7.7	7.7
Piperacillin Sodium,Tazobactam Sodium	28	6.8	6.8
Dapagliflozin	32	6.5	6.5
Mycophenilic Acid	21	6.5	6.5
Lenvatinib	33	6.5	6.5
Rifampicin	10	6.3	6.3
Granisetron Hydrochloride	10	6.1	6.1
Daspone	9	5.9	5.9
Dapsone Gel, 5%	9	5.9	5.9
Vemurafenib	11	5.8	5.9
Paclitaxel	87	5.7	5.7
Paclitaxel (Aibumin-Bound)	72	5.7	5.7
Basiliximab	10	5.4	5.4
Mycophenolate Mofetil	112	5.4	5.4
Mycophenolate Mofetil Hydrochloride	112	5.4	5.4
Vancomycin Hydrochloride	55	5.4	5.4
Dapsone	9	5.4	5.4
Vancomycin	48	5.4	5.4
Baricitinib	8	5.3	5.3
Mycophenolic Acid	26	5.2	5.2
Tacrolimus Ointment 0.1%	97	5.1	5.1
Tacrolimus Extended-Release Capsules	97	5.1	5.1
Loperamide Hydrochloride Oral	8	5.0	5.0
Bevacizumab	94	5.0	5.0
Tacrolimus	115	4.8	4.8
Prednisolone	130	4.7	4.7
Prednisolone Oral	130	4.7	4.7
Prednisolone Oral Solution	130	4.7	4.7
Ceftriaxone Sodium	27	4.5	4.5
Encorafenib	7	4.5	4.5
Ceftriaxone	23	4.5	4.5
Felodipine Extended-Release Tablets	8	4.5	4.5
Felodipine	8	4.5	4.5
Atazanavir	10	4.4	4.4
Voclosporin	6	4.4	4.4
Entecavir	8	4.4	4.4
Cefepime Hydrochloride	11	4.4	4.4
Dabrafenib	14	4.2	4.3
Dolutegravir Sodium	6	4.2	4.2
Trametinib	16	4.2	4.2
Cefepime	9	4.0	4.0
Loperamide Hcl	8	4.0	4.0
Cisplatin	46	3.8	3.8
Amikacin	9	3.4	3.4
Empagliflozin	32	3.0	3.0
Granisetron	5	3.0	3.0
Ado-Trastuzumab Emtansine	4	3.0	3.0
Tenofovir Disoproxil Fumarate	15	2.9	2.9
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	4	2.8	2.8
Gefitinib	4	2.8	2.8
Daptomycin	4	2.8	2.8
Sunitinib Malate	17	2.8	2.8
Deferasirox	11	2.6	2.7
Emicizumab	5	2.6	2.6
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	4	2.5	2.5
Gemcitabine Hydrochloride	21	2.5	2.5
Oxaliplatin	27	2.3	2.3
Sevelamer Carbonate	4	2.2	2.2
Olaparib	7	2.1	2.1
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	6	2.1	2.1
Crizotinib	4	2.0	2.0
Peginterferon Beta-1A	4	1.9	1.9
Cabozantinib	14	1.9	1.9
Emtricitabine And Tenofovir Disoproxil Fumarate	13	1.8	1.8
Emtricitabine And Tenofovir Alafenamide	3	1.7	1.7
Palivizumab	4	1.7	1.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.